Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials
Beyond diabetes and weight loss GLP-1 drugs have exploded in use in recent years for diabetes and weight loss, and they have shown benefits for a wide range of other health conditions, such as protecting the heart and kidneys, reducing sleep apnea and potentially helping with addiction
And so, we think that is another driver of growth is this will broaden access to about an additional 18 million people, starting this summer.So, the next phase of the diabesity market comes down to execution, lower cost and scaled supply in the mass market, and innovation and differentiation to compete in the premium segment
In 2026, AstraZenecas partnership with Chinas CSPC reflects growing interest in accessing Chinese innovation and manufacturing capabilities
